4th Annual Neuropsychiatric Drug Development Summit
Categories:
Prescription Medicines, Events
SEPTEMBER 29–30, 2021 | VIRTUAL EVENT
Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates
Clinical & Regulatory Challenges in Developing Psychedelics as Therapeutics
- Designing clinical trials that meet regulatory requirements without inadvertently stifling market access
- Managing the impact of CSA Schedule 1 status during development
- Building an optimal case for appropriate down-scheduling post-approval
